Phase I trial evaluating the tolerability and pharmacokinetic of multiple ascending doses of MEM 63908 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2008
At a glance
- Drugs Facinicline (Primary)
- Indications Dementia; Neurological disorders; Psychotic disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Memory Pharmaceuticals
- 26 Sep 2008 Status changed from planning to completed as reported by a Memory Pharmaceuticals media release.
- 12 Mar 2008 New trial record.